Transdermal delivery system comprising buprenorphine

a technology of buprenorphine and transdermal therapy, which is applied in the direction of biocide, drug composition, bandages, etc., can solve problems such as the potential to be subject to illicit us

Inactive Publication Date: 2014-12-11
LTS LOHMANN THERAPIE-SYST AG
View PDF4 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]It is an object of certain embodiments of the present invention to provide a transdermal therapeutic system for the transdermal administration of buprenorphine (e.g., buprenorphine base) which requires a relatively small area of release.
[0078]Within the meaning of this invention, the term “additional larger active agent-free self-adhesive layer structure” refers to a self-adhesive layer structure that is free of active agent and larger than the active agent-containing structure and providing additional area adhering to the skin, but no area of release of the active agent, and enhancing thereby the overall adhesive properties of the TS.

Problems solved by technology

However, the long administration periods may cause problems with skin irritation, which in combination with the considerable size (i.e., area of release) of the TTS may be problematic.
Also, the large amount of excess drug in the TI'S necessary to sustain enough driving force for sustaining the appropriate drug delivery over the long period of time is costly and has the potential to be subject to illicit use.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal delivery system comprising buprenorphine
  • Transdermal delivery system comprising buprenorphine
  • Transdermal delivery system comprising buprenorphine

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0213]The composition of the buprenorphine base-containing adhesive solution is summarized in Table 1 below.

TABLE 1Amt / unitIngredient (Trade Name)(kg)Buprenorphine base3.65Levulinic acid3.65Ethanol1.97Polysiloxane adhesive in n-heptane40.0Solids content of 73% by weight(BIO-PSA 7-4301 from Dow CorningHealthcare)n-heptane2.87Total52.14

[0214]In a stainless steel vessel, 3.65 kg of buprenorphine were suspended in 3.65 kg of levulinic acid and 1.97 kg of ethanol. With stirring, 40.0 kg of a polysiloxane adhesive in the form of a solution in n-heptane having a solids content of 73% by weight and 2.87 kg of heptane were added. The mixture was stirred until the buprenorphine base was fully dissolved, to give 52.14 kg of a buprenorphine-containing adhesive solution with 7% of buprenorphine, with a solids content of 70% (buprenorphine base-containing adhesive solution).

[0215]The buprenorphine base-containing adhesive solution was coated on an adhesive polyethylene terephthalate film (e.g., S...

example 2

[0217]The composition of the buprenorphine base-containing adhesive solution is summarized in Table 2 below.

TABLE 2Amt / unitIngredient (Trade Name)(kg)Buprenorphine base3.65Levulinic acid2.56Ethanol1.83Polysiloxane adhesive in n-heptane41.49Solids content of 73% by weight(BIO-PSA 7-4301 from Dow CorningHealthcare)n-heptane2.61Total52.14

[0218]The process of manufacture was as described for Example 1. The coating thickness was also chosen such that removal of the solvents results in a coating weight of the matrix layer of 120 g / m2 and thus resulted in 10% by weight buprenorphine base and 7% by weight levulinic acid in this matrix layer.

example 3

[0219]The composition of the buprenorphine base-containing adhesive solution is summarized in Table 3 below.

TABLE 3Amt / unitIngredient (Trade Name)(kg)Buprenorphine base3.65Levulinic acid3.65Ethanol1.97Polysiloxane adhesive in n-heptane39.46Solids content of 74% by weight(BIO-PSA 7-4201 from Dow CorningHealthcare)n-heptane3.41Total52.14

[0220]The process of manufacture was as described for Example 1. The coating thickness was also chosen such that removal of the solvents results in a coating weight of the matrix layer of 120 g / m2 and thus resulted in 10% by weight buprenorphine base and 10% by weight levulinic acid in this matrix layer.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
areaaaaaaaaaaa
areaaaaaaaaaaa
areaaaaaaaaaaa
Login to view more

Abstract

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenoφhine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.

Description

TECHNICAL FIELD OF THE INVENTION[0001]The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of buprenorphine, and processes of manufacture, uses thereof, and corresponding methods of treatment therewith.BACKGROUND OF THE INVENTION[0002]The active ingredient buprenorphine (5R,6R,7R,9R,13S,14S)-17-Cyclopropylmethyl-7-[(S)-3,3-dimethyl-2-hydroxybutan-2-yl]-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-3-ol) is a partially synthetic opiate with high potency. Cancer patients may be treated with daily doses of around 1 mg. Despite its rather high molecular weight of 467.64 daltons, it is currently used for transdermal administration. The commercial TTS product Norspan®, also known as BuTrans@, delivers buprenorphine to the skin sufficiently to treat patients in pain for a time period of 7 days (about 168 hours) and allows therefore a use of the TTS over a time period of 7 days and allows in a fixed dosing regimen a once-weekly TITS exchange....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/12A61K9/70A61K31/485
CPCA61K47/12A61K9/7053A61K9/7069A61K31/485A61K9/0014A61K9/7084A61K31/4748A61P25/04
Inventor HILLE, THOMASWAUER, GABRIELSMITH, KEVIN JOHNJOHNSON, HELEN ELIZABETHMUNDIN, GILLIAN ELIZABETH
Owner LTS LOHMANN THERAPIE-SYST AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap